Results 171 to 180 of about 107,280 (285)

Intravenous Immunoglobulin G Suppresses Heat Shock Protein (HSP)-70 Expression and Enhances the Activity of HSP90 and Proteasome Inhibitors [PDF]

, 2020
Richard J. Jones, Ramesh Singh, Fazal Shirazi, Jie Wan, Hua Wang, Xiaobin Wang, Min Jin Ha, Muhamed Baljević, Isere Kuiatse, R. Eric Davis, Robert Z. Orlowski   +10 more
openalex   +1 more source

Halorotetin B, A Novel Terpenoid Compound Derived from Marine Ascidian, Suppresses Tumor Growth by Targeting the Cell Cycle Regulator UBE2C

Advanced Science, EarlyView.
Halorotetin B, a novel small‐molecule terpenoid identified from an edible marine ascidian, exhibits strong anti‐tumor activity both in vitro and in vivo through direct targeting UBE2C to induce tumor cell cycle arrest and then lead tumor cell senescence. As a newly discovered UBE2C inhibitor, Halorotetin B can serve as a novel potential cell senescence
Shanhao Han, Jianhui Li, Yuting Zhu, Penghui Liu, Yaoyao Zheng, Muchun He, Bo Dong   +6 more
wiley   +1 more source

Synergistic Mechanisms of Traditional Chinese Medicine and Proteasome Inhibitors in Multiple Myeloma Therapy: A Comprehensive Review. [PDF]

Drug Des Devel Ther
Dai Y, Zhou Y, Chen H.
europepmc   +1 more source

Loss-of-function mutations in the dystonia gene THAP1 impair proteasome function by inhibiting PSMB5 expression [PDF]

Dylan E. Ramage, Drew W. Grant, Richard T. Timms   +2 more
openalex   +1 more source

DNA Nanoflower LYTACs Enable Efficient VEGF Degradation and Verteporfin Loading for Combined Therapy of Wet Age‐Related Macular Degeneration

Advanced Science, EarlyView.
An integrated approach that combines a DNA nanoflower VEGF degrader with photodynamic therapy is developed for the treatment of wet age‐related macular degeneration, which reduces the risk of VEGF reactivation‐induced CNV recurrence and minimizes the systemic side effects associated with photodynamic therapy.
Mengxuan Li, Yan Yue, Sijin Wu, Xinyu He, Jiayi Song, Shuwen Ma, Haokun Zhang, Chenyu Xu, Song Chen, Yanming Huang, Songbo Xie, Hua Yan   +11 more
wiley   +1 more source

Design, Synthesis, and Evaluation of Aza-Peptide Michael Acceptors as Human 20S Proteasome Inhibitors: Extension to the Prime Site. [PDF]

ACS Omega
Border SE, Lotti Diaz LM, Amer R, Noonchester AM, Kucway KS, Fleisher M, Fernandez JP, Lovins AR, Corrigan TS, Serrano AK, Caffrey CR, O'Donoghue AJ, Benson DM, Hadad CM, Doğan Ekici Ö.   +14 more
europepmc   +1 more source

Proteasome Inhibitors and Their Potential Applicability in Osteosarcoma Treatment. [PDF]

Cancers (Basel), 2022
Van Stiphout CM, Luu AK, Viloria-Petit AM.   +2 more
europepmc   +1 more source

Acetylation Regulates ACSL4 Degradation Through Chaperone‐Mediated Autophagy to Alleviate Intervertebral Disc Degeneration

Advanced Science, EarlyView.
Intervertebral disc degeneration is triggered by ACSL4 accumulation‐mediated ferroptosis of nucleus pulposus cells due to CMA dysfunction. KAT2B promotes ACSL4 degradation via CMA through acetylation. AAV‐mediated LAMP2A delivery or engineered exosomes rescue nucleus pulposus cell senescence and disc degeneration.
Zhouwei Wu, Zhichen Jiang, Chenglong Hong, Shu Yang, Shuqing Jin, Chenyu Wu, Kaijie Guo, Jiang Liu, Shaobo Xu, Chenggui Wang, Xiangyang Wang   +10 more
wiley   +1 more source

Efficacy of maintenance or consolidation therapy for multiple myeloma based on proteasome inhibitors: a meta-analysis. [PDF]

Discov Oncol
Wu D, Wang F, Yang X, Yang B, Chen J, Cheng J, Wei B, Yuan X, Tian T, Liu Z, He Z, Liu Y, Li Y.   +12 more
europepmc   +1 more source

Mechanisms of preferential bone formation in myeloma bone lesions by proteasome inhibitors. [PDF]

Int J Hematol, 2023
Nakaue E, Teramachi J, Tenshin H, Hiasa M, Harada T, Oda A, Inoue Y, Shimizu S, Higa Y, Sogabe K, Oura M, Hara T, Sumitani R, Maruhashi T, Yamagami H, Endo I, Tanaka E, Abe M.   +17 more
europepmc   +1 more source